Nabota is a highly purified botulinum toxin type A (150 kDa core protein) produced by Daewoong Pharmaceutical in South Korea. In clinical practice it is used to manage a spectrum of neurologic, autonomic, and glandular disorders that result from excessive muscle or secretory activity. If you need to stock the product, you can buy nabota from authorized medical suppliers.
Approved medical indications
- Cervical dystonia (spasmodic torticollis)
- Pathophysiology: involuntary neck muscle contractions leading to abnormal posture.
- Typical dosing: 150–200 U total, divided into 0.1 mL aliquots (≈2.5–5 U per injection site), administered across 8–12 sites.
- Key trial data: In a double‑blind, placebo‑controlled Phase III (n=210), Nabota reduced the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) severity score by 31 % versus 15 % in the placebo group (p<0.001). Median time to onset was 2 weeks; duration of effect ≈12 weeks.
- Upper‑limb spasticity (post‑stroke, traumatic brain injury)
- Pathophysiology: hyper‑excitability of the stretch reflex causing increased tone.
- Typical dosing: 200–300 U per affected limb, distributed across 6–10 target muscles (e.g., biceps brachii, flexor carpi radialis).
- Key trial data: A 12‑week RCT (n=156) reported a mean decrease of 1.2 points on the Ashworth Scale vs. 0.5 points for placebo (p<0.01). Patient‑reported spasticity relief lasted 12–16 weeks.
- Lower‑limb spasticity (post‑stroke, multiple sclerosis)
- Typical dosing: 300–400 U per leg, targeting gastrocnemius, soleus, and hamstrings.
- Clinical outcomes: In a multicenter study (n=94), 68 % of patients achieved a ≥1‑grade improvement in the Modified Ashworth Scale, with effects persisting 14 weeks on average.
- Chronic migraine (≥15 headache days/month, ≥8 migraine days)
- Typical dosing: 155 U across 31 injection sites ( forehead, temporalis, occipitalis, cervical paraspinals).
- Key data: A 24‑week, placebo‑controlled trial (n=348) demonstrated a reduction of 8.2 headache days per month vs. 5.1 days in the placebo arm (p<0.001). Quality‑of‑life scores (Migraine‑Specific Quality‑of‑Life) improved by 18 %.
- Primary axillary hyperhidrosis
- Typical dosing: 50 U per axilla (25 U per site × 2 sites) – total 100 U.
- Clinical response: In a 16‑week study (n=124), 68 % of participants achieved a >50 % reduction in gravimetric sweat production (p<0.001). Effects lasted 4–6 months.
- Overactive bladder (OAB) and detrusor overactivity (DO)
- Typical dosing: 100 U intra‑detrusal, administered as 20 injections of 5 U each (0.1 mL per site).
- Evidence: A 12‑week, multicenter RCT (n=230) reported a mean reduction of 2.8 urgency episodes per day vs. 1.5 in the placebo group (p=0.018). Urodynamic parameters (maximum cystometric capacity) improved by ≈30 %.
- Other neurologic indications (blepharospasm, strabismus, hemifacial spasm)
- Typical dosing: 1.25–2.5 U per injection site; total dose rarely exceeds 50 U per session.
- Clinical outcomes: Small cohort studies (n≈30) show symptom relief in 70–80 % of patients for up to 3 months.
Clinical evidence & key numbers
Real‑world data from the Nabota post‑marketing surveillance program (n=1,540) revealed:
- Overall response rate (≥50 % improvement) across all approved indications: 78 %.
- Median duration of effect: 13.4 weeks (range 10–18 weeks).
- Incidence of neutralizing antibodies: <0.5 % (reflecting the high purity of the 150 kDa toxin).
- Injection‑related pain reported by 12 % of patients, most commonly mild and transient.
“